Floatz logo

Carboplatin

Chemotherapy, Adjuvant

Shanghai Pulmonary Hospital, Shanghai, ChinaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Chemotherapy, Adjuvant cohort.

Asset / SponsorPhaseRating
American Ginseng
West China Hospital
Phase 4BB
FLUOROURACILUM
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Phase 3BB
Nuvastatic
Natureceuticals Sdn Bhd
Phase 3BB
Epirubicin
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Phase 3B
Cyclophosphamide
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Phase 3B
Epoetin Alfa
Ortho Biotech Products, L.P.
Phase 3B
CIS-DIAMMINEDICHLOROPLATINUM II
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2CCC

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →